Management of High Grade Dysplasia patients
Cancer Alliance | National | ||
---|---|---|---|
Number of High Grade Dysplasia patients in audit | 32 | 1120 | |
Cancer Alliance | National | ||
Method of Diagnosis | |||
– First diagnosis confirmed by second pathologist | N/A | 87.5% | 90.0% |
Treatment planning | |||
– HGD plan discussed at MDT | N/A | 84.4% | 93.0% |
– Treatment plan for active treatment | N/A | 53.3% | 82.0% |
First treatment | |||
– Endoscopic therapy (such as endoscopic resection) | N/A | 46.7% | 78.0% |
– Surveillance | N/A | 23.3% | 11.0% |
NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.
Management of oesophago-gastric cancer patients
Organisation | National | ||
---|---|---|---|
Number of oesophago-gastric (OG) cancer patients in audit | 82 | 19,865 | |
Case ascertainment for OG cancer (%) | 85-100% | ||
Method of Diagnosis | |||
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations |
<10 | 10.5% | 13.1% |
– Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
Pre-treatment staging of cancer | |||
– Patients having staging CT scan recorded | N/A | 94.0% | |
Treatment planning | |||
– Patients having a plan for curative treatment | 22 | 26.8% | 37.2% |
– Patients having a plan for non-curative treatment | 60 | 73.2% | 62.8% |
– Patients with non-curative plans having chemotherapy or radiotherapy | N/A | 34.7% |